Name: Citius Pharmaceuticals Inc (CTXR) Fundamental & Financial Data
Creator: Stocktwits

SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD shares faced sharp downward pressure after-hours despite reporting strong earnings and revenue growth, as investors reacted to high market expectations and concerns over increased capital expenditures. The community is currently divided between bears highlighting valuation and profitability worries, and long-term bulls who view the pullback as a buying opportunity given the company's central role in the expanding AI infrastructure cycle.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is experiencing intense volatility as investors weigh a significant revenue beat and ambitious long-term AI infrastructure plans against concerns regarding heavy capital expenditure and upcoming share lock-up expirations. The community is sharply divided, with bulls pointing to the company's massive growth potential in space and AI, while bears remain focused on its lofty valuation, cash burn, and the potential supply pressure from the imminent release of millions of insider shares.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune is trending as investors brace for the upcoming PDUFA decision, with community sentiment deeply divided over whether the stock's recent surge reflects inevitable approval or a setup for a potential third Complete Response Letter (CRL). While bulls are energized by the recent positive Advisory Committee vote and the prospect of a short squeeze, skeptics are expressing concern over the company's precarious cash runway, the prospect of future equity dilution, and lingering questions regarding the clinical trial data.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently seeing significant momentum driven by a series of new contract wins and a rapidly growing backlog, which has helped the stock decouple from the volatility surrounding SpaceX. Investors are actively debating the company's long-term potential as an end-to-end space platform while keeping a close watch on upcoming earnings and Neutron program developments.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is surging following a blowout quarterly earnings report that featured massive revenue growth and increased full-year guidance, fueling heavy buying momentum. The community is actively debating the stock's valuation, with many long-term bulls celebrating the company's AI sovereign market positioning while shorts face significant losses.

Redwire Corp. engages in the development and provision of space and defense technologies and mission-critical solutions for government, commercial, and civil customers. Its offerings include spacecraft platforms, space infrastructure, avionics, sensors and payloads, power generation systems, radio frequency systems, microgravity research and manufacturing technologies, autonomous systems, optical sensors, and digital engineering solutions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corp is seeing a surge in investor interest driven by a combination of new defense contracts, expansion of its space-based manufacturing infrastructure, and increased institutional positioning. Market participants are actively discussing the stock's valuation relative to competitors, its role as a key supplier for national security and pharma research in space, and the potential for upward momentum leading into its next earnings report.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is experiencing intense investor scrutiny and volatility as the market weighs strong global Wegovy pill demand against pipeline setbacks, including recent cardiovascular trial failures. The community is actively debating the company's long-term competitive positioning versus Eli Lilly and expressing significant frustration over communication strategies and management's handling of trial outcomes.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending as investors weigh strong Q2 revenue growth and raised 2026 outlook against recent volatility and short-seller pressure. The community is focused on the potential for a short squeeze and evaluating the company's scaling milestones alongside the broader defense-sector demand for their silicon-anode battery technology.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense is trending as investors react to a significant influx of government contract wins and defense funding, sparking intense community debate about whether the current price represents a buying opportunity or a deeper structural decline. While bullish traders are focused on the company's expanding backlog in hypersonic and drone technologies, others remain cautious, pointing to persistent margin pressures and skepticism regarding the stock's long-term valuation.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

Better Home & Finance is trending as the community debates a sudden leadership transition that saw the founder step down, while investors digest preliminary earnings data that highlights significant revenue growth despite a net loss. Sentiment remains sharply divided between those who view the management change as a catalyst for future profitability and cost discipline, and skeptics who are concerned about the stock's recent volatility and the company's long-term path to becoming a profitable, AI-driven mortgage platform.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption PR Newswire CRANFORD, N.J., July 21, 2026 Expanded...

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin...

Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting PR...

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides...

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and...

Citius Oncology Ships First International Order of LYMPHIR to Europe

Citius Oncology Ships First International Order of LYMPHIR to Europe Citius Oncology Ships First International Order of LYMPHIR to Europe PR Newswire CRANFORD, N.J., April 29, 2026 Order fulfilment expands international patient access to LYMPHIR following initial U.S. launchDistribution by regional...

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules Citius Pharmaceuticals Announces Closing of Registered Direct Offering of...

What's Behind The Drop In Citius Pharmaceuticals?

Citius Pharmaceuticals (NASDAQ:CTXR) shares tumbled on Friday after it announced a registered direct offering, raising dilution concerns.read more...

Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced...

Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development

Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting...

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone, Leonard Mazur, Myron Holubiak on January 23, 2007 and is headquartered in Cranford, NJ.

Citius Pharmaceuticals Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.6225
Prev Close	$0.596
Open	$0.6027
Dividend Yield	0.00%
50-Day Moving Average	$0.5728
Beta	1.47
Avg. Volume	430,637.01
PE Ratio	-0.24

52-Week High	$2.19
52-Week Low	$0.4687
Market Capitalization	$16.36M
EPS (Annual)	-$3.38
Price to Book	0.23
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info